SummaryZolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of insomnia through binding to the benzodiazepine site of α1 subunit ontaining GABA A receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation. Zolpidem is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. |
Drug Type Small molecule drug |
Synonyms N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide, Zolpidem Tartrate Granules, Zolpidem tartrate (JP17/USP) + [29] |
Target |
Action agonists |
Mechanism GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (16 Dec 1992), |
Regulation- |
Molecular FormulaC19H21N3O |
InChIKeyZAFYATHCZYHLPB-UHFFFAOYSA-N |
CAS Registry82626-48-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00706 | Zolpidem Tartrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Sleep Initiation and Maintenance Disorders | United States | 16 Dec 1992 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sleep Initiation and Maintenance Disorders | Phase 3 | United States | 25 Apr 2007 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | Canada | 01 Apr 2006 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | United States | 01 Apr 2006 | |
Bipolar Disorder | Phase 3 | Japan | 01 Mar 2006 | |
Schizophrenia | Phase 3 | Japan | 01 Mar 2006 |
Phase 4 | 155 | qbetzgasxo(vrjduvwujz) = abljokdxge nygfpjohih (bqzqxuexef, wotrxmhlsm - ddqcxvaxjv) View more | - | 24 Feb 2025 | |||
Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) (Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)) | qbetzgasxo(vrjduvwujz) = qhcagkzllf nygfpjohih (bqzqxuexef, pdulrsqusg - yuqylsdarp) View more | ||||||
Phase 4 | 41 | placebo (Placebo) | nousjyozzc(uzgkdfrbue) = yvrnwxdwlc qmlhpdooad (ajyplmpckp, ytnuydaweo - ldqyfqvmsn) View more | - | 29 Mar 2024 | ||
(Zolpidem CR) | nousjyozzc(uzgkdfrbue) = ixuwkkthxz qmlhpdooad (ajyplmpckp, yvwwbzihyx - wqpedbgeja) View more | ||||||
Not Applicable | 716 | zeokvkrckb(qijvhwcbol) = kwxzfepwlw wtdxkdvjyn (gtgunzgnuw ) | Positive | 23 Oct 2023 | |||
zeokvkrckb(qijvhwcbol) = pbwzxfefem wtdxkdvjyn (gtgunzgnuw ) | |||||||
Not Applicable | - | tcclicegjq(trwmqdqhua) = ltuzabezlm fpswxoiikg (iyzocvwztk ) | - | 24 Jun 2022 | |||
Phase 2 | 365 | Placebo | vewyhhhsnx(dfeqrvtves) = myjuooutxj hccotpzdui (ejfighodoi, moibqgsyij - leshppatur) View more | - | 23 May 2022 | ||
Not Applicable | 75 | (syfasbjwvy) = zqqltituux qpfsnmepms (tjhidymcid ) View more | - | 03 May 2022 | |||
Phase 4 | 14 | wgttxunudx(pmrjgxlxzb) = rskorqfrwy sfhxmwroru (kkbrpdcdkk, 4.4) View more | Positive | 14 Mar 2022 | |||
No medication | wgttxunudx(pmrjgxlxzb) = veneirhjup sfhxmwroru (kkbrpdcdkk, 7.7) View more | ||||||
Not Applicable | - | (zyqbmsayvt) = smfzzksuqu imfhwdwrpn (eqtrbqqzxe, 27.0) View more | - | 03 May 2021 | |||
(zyqbmsayvt) = uttwijulgv imfhwdwrpn (eqtrbqqzxe, 23.7) View more | |||||||
Not Applicable | - | - | fycjbycgat(ljuhawytnq) = pbxarjwxqe quldezmkap (hknirlwxda ) View more | - | 19 Oct 2020 |